3.1. Cardiovascular Toxicity Risk Stratification before Anticancer Therapy
cancer, cardiotoxicity, Cardiovascular toxicity
CANCER
Cardiovascular toxicity risk assessment was accomplished for every patient, and modification of the risk factors was suggested, including the recommendation for moderate physical activity during cancer treatment. Most patients (83%) were classified as having a low cardiotoxicity risk. However, four patients in the ivabradine group and three in the control group were at intermediate risk (due to age > 65 years and multiple CV risk factors), and one patient in the control group was at high risk of cardiotoxicity (because of previous anthracycline use).